Mitochondrial swelling and reduced viability in kidney-derived cells
Cell-based study · Opossum kidney (OK) proximal-tubule-derived cell line [2]
Deferasirox decreased 24-hour viability and caused rapid mitochondrial swelling. Mitochondria retained TMRM signal during acute swelling, while FCCP dissipated it. Other iron chelators did not reproduce the swelling. Iron co-treatment prevented swelling, and subsequent iron addition reversed it; albumin also reduced toxicity. These controls belong to the same cellular toxicity investigation.
| Endpoint | Reported result | Reference |
|---|---|---|
| Cell viability relative to control after 24 hours | IC50 246 µM; n = 3 (replicate type not specified in caption) | [2] |
| Mitochondrial morphology and membrane-potential-sensitive fluorescence | qualitative response 200 µM DFX: marked swelling by 30 minutes with retained TMRM signal; most mitochondria remained energized at 3 hours | [2] |
| Prevention and reversal of mitochondrial swelling | qualitative rescue Iron(III) 200 µM with DFX 200 µM prevented swelling; iron added 10 minutes after DFX reversed swelling. Albumin 200 µM pretreatment for 5 minutes prevented swelling and preserved 24-hour viability (n = 3, mean ± SEM). | [2] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 200 µM for acute imaging; concentration-response series for the 24-hour viability IC50
- Exposure duration
- 30 minutes for representative swelling images; tracking up to 3 hours; 24 hours for viability
- Method
- Cell exposure followed by live confocal imaging or Neutral Red viability assay
- Co-treatment
- Separate mechanistic controls: iron(III) 200 µM, albumin 200 µM, and FCCP 5 µM; deferoxamine and deferiprone were separate comparator treatments.
- Reported limits
- Vehicle composition for the selected Figure 1/6 cellular exposures and replicate type for the viability n = 3 are not specified in the selected main-text methods/captions. No other experiment’s vehicle is assigned.
Methods and source locations
Compound reported in the paper: Deferasirox; Compound label in the paper: DFX
Compound-level cellular observations; not validation of Adooq A10293 or a particular lot.
Figures 1a–h, 6a–c; Results: acute swelling, iron/albumin binding and recovery; Methods: Cell lines, Live imaging, Cell viability; Discussion
Cell viability relative to control after 24 hours: Neutral Red uptake; log(inhibitor) versus normalized response variable-slope analysis — Figure 1a caption; Methods: Cell viability
Mitochondrial morphology and membrane-potential-sensitive fluorescence: Live confocal imaging with TMRM and mitochondrial GFP; electron microscopy corroboration — Figure 1b–g and Results: acute mitochondrial swelling
Prevention and reversal of mitochondrial swelling: TMRM imaging and viability assay; albumin viability comparison by one-way ANOVA with Tukey multiple comparisons — Figure 6a–c caption; Results: iron/albumin binding and recovery